Summit Therapeutics (SMMT) closed at $16.33 on November 6, 2026, up 15.1% from the previous close, on volume of 5,503,273 shares (30-day average 5,859,105).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 13, 2026 | Call Spread | 15-Jan-2720 : 25 C | 10,006 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Catalyst Watch: Post-election positioning, Anthropic IPO buzz, and Adobe event
Seeking Alpha News (Fri, 6-Nov 3:00 PM ET)
Summit Therapeutics (SMMT) Receives a Buy from Citi
TipRanks (Fri, 6-Nov 9:22 AM ET)
TipRanks (Thu, 5-Nov 5:31 PM ET)
TipRanks (Thu, 5-Nov 10:30 AM ET)
TipRanks (Thu, 5-Nov 9:30 AM ET)
Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT)
TipRanks (Thu, 5-Nov 9:29 AM ET)
TipRanks (Thu, 5-Nov 6:40 AM ET)
Summit Therapeutics Files Prospectus Supplement for Share Issuance
TipRanks (Wed, 4-Nov 6:38 PM ET)
Summit Therapeutics Stockholders Approve Increase in Authorized Shares
TipRanks (Wed, 4-Nov 6:22 PM ET)
Summit Therapeutics Non-GAAP EPS of -$0.20 beats by $0.08
Seeking Alpha News (Wed, 4-Nov 5:07 PM ET)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Summit Therapeutics trades on the NASDAQ stock market under the symbol SMMT.
As of November 6, 2026, SMMT stock price climbed to $16.33 with 5,503,273 million shares trading.
SMMT has a beta of 2.51, meaning it tends to be more sensitive to market movements. SMMT has a correlation of 0.18 to the broad based SPY ETF.
SMMT has a market cap of $13.03 billion. This is considered a Large Cap stock.
Last quarter Summit Therapeutics reported $0 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-53,790 and exceeded earnings estimates by $.02.
In the last 3 years, SMMT traded as high as $36.91 and as low as $1.64.
The top ETF exchange traded funds that SMMT belongs to (by Net Assets): VTI, VB, XBI, VBR, VXF.
SMMT has underperformed the market in the last year with a return of -11.5%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SMMT shares. However, SMMT has outperformed the market in the last 3 month and 2 week periods, returning +20.6% and +5.6%, while SPY returned -4.1% and -3.2%, respectively. This indicates SMMT has been having a stronger performance recently.
SMMT support price is $13.52 and resistance is $14.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SMMT shares will trade within this expected range on the day.
